



Antifungal Drugs

Barbara D. Alexander, MD, MHS, FIDSA
Duke University

8/8/2026



Disclosures of Financial Relationships with Relevant Commercial Interests

- Consultant: Scynexis/GSK, HealthTrackRx, DevleBio, Anvil Diagnostics
- Research Grant to My Institution: Karius
- Clinical Trials (Site PI/Study PI): Scynexis, F2G, Basilea
- Royalties: UpToDate, Biomeme

Agenda

1. Review of Antifungals
 - Antifungal Classes / Mechanisms of Action
 - Distinguishing properties of most common drugs
2. Questions on antifungals with answers
3. New stuff (not on boards)

Reasons for Treatment Failure

“Clinical”

Host defense inadequate

- Underlying disease uncontrolled
- Persistent neutropenia / Immunosuppressive drug use

Drug exposure inadequate

- Toxicity / Non-compliance / Not absorbing
- Persistent nidus / Protected site
- Drug interactions

“Microbiologic”

Microbial resistance

- Intrinsic - present for all members of the species despite lack of drug exposure
- Acquired - develops after exposure to a drug

5 Antifungal Drugs

Speaker: Barbara Alexander, MD, MHS, FIDSA

Antifungal Resistance Altered Target Enzymes

1. AZOLE RESISTANCE IN CANDIDA and ASPERGILLUS

- Fungus modifies drug target: 14- α -sterol demethylase
 - Changes in ERG11 gene (yeasts), cyp51A gene (molds)
- Azoles no longer block synthesis of ergosterol, which is necessary for cytoplasmic membrane function
- Cross resistance varies with specific mutation and azole

2. ECHINOCANDIN RESISTANCE IN CANDIDA

- Fungus modifies drug target: glucan synthase
 - Changes in FKS1 & FKS2 genes
- Echinocandins no longer block synthesis of beta-D-glucan, which is necessary for cell wall synthesis/stability
- Cross resistance between echinocandins is usual

Antifungal Resistant Species



- Amphotericin B resistant:** *Scedosporium apiospermum* complex, *Lomentosporium* (*Scedosporium*) *prolificans*, *Purpureocillium* (*Paecilomyces*) *lilacinum*, *Aspergillus terreus*; variable in *Candida lusitanae*, *C. auris*, *Fusarium* species
- Fluconazole resistant:** All molds, *Rhodotorula* species, *Candida krusei*; variable in *Candida auris* (~90%), *Candida haemulonii*, some *Candida glabrata* (~20%)
- Voriconazole resistant:** Mucorales; higher MIC's for cryptic *Aspergillus* species (*A. lentulus*, *ustus*, *calidoustus*)
- Posaconazole, Isavuconazole resistance:** Similar to voriconazole, but more activity against Mucorales
- Echinocandin resistance:** *Cryptococcus*, *Rhodotorula*, *Trichosporon*, *Mucorales*

CLSI. Epidemiological Cutoff Values for Antifungal Susceptibility testing. 4th ed. CLSI supplement M57S. Clinical and Laboratory Standards Institute; 2022.

Amphotericin B

- Compromises cell membrane (leaky)
- Induces proinflammatory cytokines: fever, myalgias
- Azotemia (less with saline loading), hypokalemia, renal tubular acidosis, anemia (erythropoietin loss)
 - Amph B deoxycholate (conventional)
 - Liposomal Ampho B (LAMB) - less toxic

Azoles

ALL AZOLES ARE TERATOGENIC; CYP3A4 DRUG INTERACTIONS

- Fluconazole: *Candida*, *Cryptococcus*, *Coccidioides*
 - Good concentration in urine & CSF
- Itraconazole: *Histoplasma*, *Blastomyces*, ringworm
 - Check blood levels
- Voriconazole: *Aspergillus*, molds other than *Mucorales*, *Candida*
 - Check blood levels; IV formula with cyclodextrin
- Posaconazole: *Aspergillus*, variable *Mucorales*
 - Check blood levels; IV formula with cyclodextrin
- Isavuconazole: *Aspergillus*, variable *Mucorales*
 - Fewer drug interactions, less QTc Prolongation than other azoles
 - Water soluble so no cyclodextrin

5 Antifungal Drugs

Speaker: Barbara Alexander, MD, MHS, FIDSA

Fluconazole THE FUNDAMENTALS

- Approved for: Candidiasis, Cryptococcosis, Prophylaxis in HSCT
- Also good for Coccidioidal meningitis, ringworm
- NO MOLD ACTIVITY*
- Side Effects: Few; rarely dry skin, alopecia*
- Distribution: Good penetration into urine and CSF*
- Wide dose range; accumulates in renal dysfunction*, requires adjustment
- Drug interactions: moderate CYP2C9 and CYP3A4

*Good Board Questions!

Voriconazole THE FUNDAMENTALS

- Invasive *Candida*; Invasive *Aspergillus*; *Scedosporium apiospermum* complex & *Fusarium* in pts with refractory dz or intolerant of other therapy
- Metabolism*: Children are rapid metabolizers; 20% Japanese slower (2C19)
- Distribution: Good CSF levels*, none in urine
- Formulations: IV contains sulfbutyl ether-B-cyclodextrin which accumulates in azotemia (use oral if CrCl <50 mL/min*)
- Drug interactions: increases many other drug levels*: cyclosporine, tacrolimus, sirolimus, steroids (budesonide, fluticasone), etc.
- Side effects*: visual changes, hallucinations, hepatitis, photosensitivity, peripheral neuropathy
 - After many months of Rx: skin cancer, periostitis*

*Good Board Questions!

Voriconazole Side Effects Photosensitivity


♪...driving in my "Beamer with the ragtop down"....
Jason Aldean



♪...love you more than that feeling when the bass hits the hook...
Morgan Wallen

Voriconazole Side Effects Skin Cancer

N=327 Lung transplant Recipients:
50 with SCC, 277 Controls



Voriconazole Prophylaxis

- 2.6-fold increased risk for SCC
- Impact dose-dependent: risk increased by 5.6% with each 60-day, 200mg BID exposure
- 28% absolute risk increase @ 5 yrs

Singer JP, et al. Journal of Heart and Lung Transplantation. 2012;31:694-69

5 Antifungal Drugs

Speaker: Barbara Alexander, MD, MHS, FIDSA

Voriconazole Side Effects

Periostitis:

- Months of Rx
- Bone pain
- Alk phos high
- Plasma fluoride high (fluorosis)
- Bone scan / X-rays
- Exostoses



Wermers, et al. CID 2011
Rossier, et al. Eur J Nuc Med Mol Imag 2011

Posaconazole THE FUNDAMENTALS

- Approved for: oropharyngeal candidiasis; prophylaxis* in GVHD or prolonged neutropenia; Invasive Aspergillosis
 - Mucormycosis *once patient has responded to amphotericin B*
- Formulations:
 - Extended-release tabs (three 100mg tablets twice daily on day 1, then 300mg daily)
 - IV same dose; contains cyclodextrin (use oral if CrCl <50 mL/min)
- Pharmacokinetics: 7-10 days for steady state; check trough levels (target usually 2-5 mcg/ml)
- Drug Interactions: increases some drug levels (CYP3A4)
- Side effects: Generally well-tolerated; hypertension, hypokalemia*

*Good Board Questions!

Isavuconazole THE FUNDAMENTALS


- Approved for: Invasive Aspergillosis (noninferior to vori); Mucorales (use is controversial)
- Not approved for Invasive Candidiasis* (inferior to caspofungin for candidemia)
- No good data on prophylaxis
- Distribution: no drug in CSF* or urine; long half life (5.4 days)
- Drug interactions: fewer than vori or posa*
- Isavuconazonium 372mg = Isavuconazole 200 mg
- Load with 200 mg q8h X 6 doses then 200 mg qd, IV or PO
- No dose change for renal* or moderate liver failure

*Good Board Questions!

Echinocandins

5 Antifungal Drugs

Speaker: Barbara Alexander, MD, MHS, FIDSA



Caspofungin, Micafungin, Anidulafungin, Rezafungin

• Indications:

- Invasive Candidiasis (caspo, mica, anidu, reza)
- Esophageal Candidiasis (caspo, mica, anidu)
- Febrile Neutropenia and Refractory Aspergillosis (caspo only*)
- Prophylaxis of *Candida* in HSCT (mica only*)
- Resistance in *Candida* can arise during long therapy
- *Cryptococcus*, *Rhodotorula* & *Trichosporon* are intrinsically resistant*
- *Aspergillus* and other mold activity is variable
- Formulations: IV only, once daily dosing.
 - Rezafungin with prolonged half-life; once weekly dosing
- Distribution: No drug in urine; protein binding high: poor penetration into CSF* and vitreous humor of eye
- Drug interactions: none important

***Good Board Questions!**

Flucytosine

- Indications: Cryptococcal Meningitis, Invasive Candidiasis
- Distribution: Capsule only; Bioavailability 100%; good levels in CSF, eye, urine*
- Drug resistance arises during monotherapy; typically used in combination with amphotericin B*
- Side Effects*: Accumulates in azotemia: bone marrow suppression, hepatitis, colitis
- Measure blood levels/dose adjust (target ~40-60 mcg/ml)

***Good Board Questions!**

Now For A Few Questions



5 Antifungal Drugs

Speaker: Barbara Alexander, MD, MHS, FIDSA

Question #1

A 47-year-old male with known HIV, poorly compliant with ARV, last CD4 20/mcl, presents with low grade fever and headache. Blood culture is growing a yeast, not yet identified.

Starting micafungin would be a poor choice if the isolate is which of the following?

- A. *Candida parapsilosis*
- B. *Cryptococcus gattii*
- C. *Candida auris*
- D. *Candida krusei*
- E. *Candida glabrata*

Question #2

A 72-year-old man with diabetes mellitus, renal failure and a central venous catheter developed fever and hypotension. Blood cultures grew *Candida lusitanae*.

On day 5 of liposomal amphotericin B 5 mg/kg he remained febrile, and his creatinine rose from 4.5 to 6.0 mg/dl.

In addition to changing his IV catheter, which of the following would be most appropriate?

- A. Itraconazole
- B. Micafungin
- C. Amphotericin B lipid complex
- D. IV Voriconazole
- E. Isavuconazole

Question #3

What is the mechanism of action of the echinocandin class of antifungals?

- A. Inhibits synthesis of membrane sterols
- B. Damages cytoplasmic membrane
- C. Interferes with synthesis of fungal cell wall glucans
- D. Inhibits fungal DNA synthesis
- E. Interfere with synthesis of fungal cell wall chitin

Question #4

A 37-year-old female with diabetes mellitus is admitted for ketoacidosis, fever and sinus pain. Biopsy of a necrotic area of the middle turbinate shows wide, branching nonseptate hyphae. Serum creatinine is 2.5 mg/dl.

Which of the following would be most appropriate?

- A. Voriconazole
- B. Anidulafungin
- C. Fluconazole
- D. Liposomal amphotericin B
- E. Itraconazole

Question #5

You are asked to advise your hem-onc colleagues as to what prophylactic antifungal agent might be useful in preventing aspergillosis in their patients with prolonged neutropenia or acute graft-vs-host disease.

According to the IDSA guidelines and literature, what would you recommend?

- A. Itraconazole solution
- B. Posaconazole
- C. Rezafungin
- D. Voriconazole
- E. Caspofungin

Question #6

45-year-old male 6 weeks post stem cell transplant for myelodysplasia, with a history of chronic hepatitis C was discharged home to Florida on cyclosporine, mycophenylate, prednisone, bactrim (TMP/SMZ), citalopram and voriconazole. Diffuse nonpruritic erythema developed over his sun exposed skin.

What was the most probable cause?

- A. Porphyria cutanea tarda
- B. Graft versus host disease
- C. Drug interaction
- D. Voriconazole
- E. Bactrim allergy

Question #7

A 66-year-old male with neutropenia following chemotherapy for lung cancer, serum creatinine 5 mg/dl, and congestive heart failure is found to have a *Scedosporium apiospermum* lung abscess.

Which of the following would be preferred?

- A. Anidulafungin
- B. Itraconazole
- C. Micafungin
- D. Oral voriconazole
- E. Liposomal amphotericin

Question #8

65-year-old admitted with cryptococcal meningitis, seizures, diabetes mellitus and granulomatosis with polyangiitis. Given conventional amphotericin B, flucytosine, phenytoin, glipizide, prednisone and cyclophosphamide.

By the end of the first week of treatment, his creatinine had risen from 1.6 to 3 mg/dl.

By the end of the second week his WBC count had fallen to 1.2K, platelets 60K and diarrhea began.

Which of these drugs is most likely the cause of his WBC falling to 1.2K, platelets 60K, and copious diarrhea?

- A. Flucytosine
- B. Phenytoin
- C. Glipizide
- D. Cyclophosphamide
- E. Cytomegalovirus

Take Home Messages...

- Ampho: NOT for *Scedosporium/Lomentosporum*, *Candida lusitanae*, or *Asperillus terreus*
- Only use ampho B as first line for mucormycosis
- Fluconazole: NOT *Candida krusei* or *Candida auris*;
+/- *Candida glabrata*
- Echinocandins: NOT for *Trichosporon*, *Rhodotorula* or *Crypto*
- Know mechanisms of action:
 - Ergosterol synthesis – azoles
 - Glucan synthesis – echinocandins
 - Ergosterol binding / leaky cell membrane – Amphotericin B
 - DNA synthesis – Flucytosine
- Flucytosine: leuko- and thrombo-cytopenias, diarrhea, hepatitis

Take Home, continued...

- Voriconazole: phototoxicity, periostitis, skin cancer, visual disturbances and hallucinations
- Azole drug interactions:
 - Increases other drug levels: cyclosporine, tacrolimus, sirolimus, warfarin, midazolam, steroids, etc.
 - Some drugs decrease azole levels: phenytoin, rifampin, etc.

Thank You

barbara.alexander@duke.edu

New Oral Antifungals Approved for Vulvovaginal Candidiasis

Ibrexafungerp – novel ORAL glucan synthase inhibitor (triterpenoid)

- Acute infection: 300mg 12 hours apart on same day
 - Cost: \$ 475
- Recurrent infection: 300mg bid monthly for 6 months
 - Cost: \$2,992

Otesaconazole – azole with long half life (drug persists about 2 years)

- Recurrent infection (in women not breastfeeding/capable of childbearing)
- One week of fluconazole or otesaconazole then otesaconazole once a week for 11 weeks
 - Cost: \$2,966

Investigational Antifungals in Clinical Trials

- **Olorofim.** Orotomide; Inhibits DHODH* (pyrimidine, cell wall synthesis)
 - PO
 - *Aspergillus*, *Coccidioides*, *Scedosporium*, *Lomentospora* (not Mucorales or yeast)
- **Fosmanogepix.** Oxazole; Inhibits GWT1** (mannoprotein transport & anchoring)
 - PO, IV
 - *Candida* (not *C. krusei*), *Aspergillus*, *Fusarium*, *Scedosporium*, (not Mucorales)
- **Encochleated amphotericin B:** PO. Multilayered sheets of lipids.
 - *Cryptococcus*, *Aspergillus*
- **Opelconazole:** Aerosol. Prophylaxis; Chronic aspergillosis

*DHODH – Dihydroorotate dehydrogenase

**GWT1 - Glycosylphosphatidylinositol-anchored Wall protein Transfer 1

5 Antifungal Drugs

Speaker: Barbara Alexander, MD, MHS, FIDSA